### Page 1 – BK220697 – Steven Hwang



MEDI-KHAN USA INC February 9, 2023

Attention: Steven Hwang 655 North berry St., Suite A

Brea, CA 92821

Email Address: (b) (6)

Re: BK220697 (Formally K121703)

Trade/Device Name: LIPOKIT WITH DISPOSABLE 50CC AFT SYRINGE

Regulation Number: 21 CFR 878.5040 Regulation Name: Suction lipoplasty system

Regulatory Class: Class II Product Code: QKL; QUB

Dear Mr. Hwang:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated December 7, 2012. Specifically, FDA is updating this SE Letter because FDA has assigned your submission a new submission tracking number and created a new product code to better categorize your device technology.

Please update the registration and listing of the device within the FURLS Device Registration and Listing Module according to <a href="http://www.fda.gov/">http://www.fda.gov/</a>

<u>MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/ucm053185.htm.</u>

For more information, please refer to the Federal Register Notice Consolidation of Devices That Process Autologous Human Cells, Tissues, and Cellular and Tissue-Based Products at the Point of Care To Produce a Therapeutic Article (86 FR 50887, available at

https://www.federalregister.gov/documents/2021/09/13/2021-18912/consolidation-of-devices-that-process-autologous-human-cells-tissues-and-cellular-and-tissue-based).

### Page 1 – BK220697 – Steven Hwang

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact the Regulatory Project Manager, Candace Jarvis at (240) 402-8315 or by email at <a href="mailto:Candace.Jarvis@fda.hhs.gov">Candace.Jarvis@fda.hhs.gov</a>.

Sincerely,

Wilson W. Bryan, MD Director Office of Tissues and Advanced Therapies Center for Biologics Evaluation and Research

### Medi-Khan (USA) Inc.

### Lipokit with disposable 50cc AFT Syringe Special 510(k) Notification

DEC 7 2012

### 510(k) Summary

This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) summary is provided in conformance with 21 CFR Part 807.92.

### I. Sponsor's Information

Name:

Medi-Khan USA, Inc.

Address:

705 S Ave 61, Los Angeles, CA 90042

Phone:

(323)259-5000

Fax:

(323)259-5005

**Contact Person:** 

Peter Jung, Vice President & C.O.O

Tel: (323) 259-5000 Fax: (323) 259-5005

Email: peter2275@gmail.com

Official Correspondent:

Kachi Enyinna,

Principal Consultant

510K Technology Group, LLC 399 Massachusetts Avenue, Suite 2

Boston, MA 02115 (240) 994-4242

Establishment Reg. No.:

3007134825

Date Prepared:

June 8, 2012

#### II. Device Name

Trade Name:

Lipokit with disposable 50cc AFT Syringe, model LK-101

Common Name:

Suction Lipoplasty System

Classification Name:

System, Suction, Lipoplasty

Classification Number:

878.5040

**Product Code:** 

MUU

Classification Panel:

General and Plastic Surgery

#### III. Predicate Device

Lipokit with disposable 50cc AFT Syringe (K083455)

### Medi-Khan (USA) Inc.

### Lipokit with disposable 50cc AFT Syringe Special 510(k) Notification

#### IV. Indications for Use

The Lipokit is used in the tumescent injection, aspiration, harvesting, filtering and transferring of autologous fat tissue.

The Lipokit is intended for use in the following surgical specialities when the aspiration of soft tissue is desired:

- Plastic and Reconstructive Surgery
- General Surgery
- Dermatological Surgery
- · Obstetrician & Gynecological Surgery
- Cosmetic Surgery

The Lipokit is indicated for use when harvesting of highly concentrated pure fatty tissues for aesthetic body and facial contouring is desired.

### V. Device Description

### **Design Characteristics**

The Lipokit with disposable 50cc AFT Syringe is composed of one centrifuge unit with a motor for suction and positive pressure; a 50cc AFT (autologous fat transfer) syringe with weight-mesh piston, a cannula and other ancillary parts. The vacuum and positive pressure are controlled using a foot pedal control switch.

The Lipokit is a sterile, single-use, manual device consisting of a cannula, and tissue collection container (the 50cc AFT Syringe) that relies on the centrifuge unit for its energy supply. The cannula is attached directly to the 50cc AFT Syringe which simplifies and reduces the steps needed in the collection, filtering and transfer of the autologous fat. In so doing, the harvested fat is less traumatized and risk of contamination is lowered because the fat never leaves the harvesting syringe until reinjection. The cannula is a hollow tube with an opening near the tip to communicate the centrifuge unit to the tissues and subsequently aspirate, harvest and filter subcutaneous fatty tissues from the patient into the collection container (the 50cc AFT Syringe).

The stainless steel cannula that contacts the patient is provided a various sizes ranging from 2.5 – 4.0mm in diameter. The tip region of the cannula may have a single or multiple openings that range in size from 170mm to 260mm in length distributed uniformly or randomly though the end of the cannula.

The 50cc AFT Syringe is a polymeric 50cc volume luer-lock style, single-use syringe consisting of a polypropylene barrel with printed graduations and a weight-mesh piston composed of polycarbonate.

### Medi-Khan (USA) Inc.

### Lipokit with disposable 50cc AFT Syringe Special 510(k) Notification

**Material Composition** 

No change in material composition. The components of Lipokit that have direct patient contact are fabricated from surgical stainless steel.

### Sterility

Sterility requirements as approved in the original device has not changed for the modified device. The 50cc AFT Syringe is sterilized by ethylene oxide (EtO) gas.

### **Design and Materials**

The design and materials of the modified Lipokit with disposable 50cc AFT Syringe remains the same as the legally cleared Lipokit with disposable 50cc AFT Syringe. The only change to the design of the cleared Lipokit is the addition of a transformer to step down the voltage input of the Lipokit from 220V/60Hz to 120V/60Hz. The engery source has not been modified and remains the same as the cleared Lipokit. Other than the change in voltage input requirement for the Lipokit, there are no other changes to the design, material, intended use or fundamental scientific technology.

### **Technological Characteristics**

There are no changes in the technological characteristics to the previously cleared Lipokit with disposable 50cc AFT Syringe. The Lipokit with disposable 50cc AFT Syringe incorporates changes pertaining only to the addition of the transformer to step down the voltage of the Lipokit from 220V/60Hz to 120V/60Hz for use in U.S. market. There were no hardware changes made in the machine to accommodate this modification. The following technical specifications of the modified device remain the same as the unmodified device:

- Safety System
- System performance
- Environmental requirements
- Transportation and Storage condition
- User Interface
- Hardware
- Accessories
- Alarms
- Accuracy and Controls
- Protection against Mechnical Hazard
- Protection against Electrical Hazard
- Protection against excessive temperature or other hazards
- Manufacturing Location and manufacturing processes (assembly, fabrication, testing, shipping, installation and service).

#### VI. Performance Data

Based on the Risk Analysis, the modified Lipokit was tested for electrical safety and electromagenetic compatiblity in accordance to IEC 60601-1:1998, Am1:91, Am2:95 and

V12 1703

# Medi-Khan (USA) Inc.

### Lipokit with disposable 50cc AFT Syringe Special 510(k) Notification

IEC 60601-1-2:2007, Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic Compatibility - Requirements and tests (Edition 3).

### VII. Equivalence to Market Product

The modified Lipokit with disposable 50cc AFT Syringe has the same indicated use, same operating principle, same design, same materials, shelf life and is packaged and sterilized using the same material and processes as the cleared Lipokit (K083455).

In summary, the modified Lipokit described in this submission are, in our opinion, substantially equivalent to the cleared Lipokit with disposable 50cc AFT Syringe.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-002

Medi-Khan USA, Inc. % 510K Technology Group, LLC Mr. Kachi Enyinna 399 Massachusetts Avenue, #2 Boston, Massachusetts 02115

December 7, 2012

Re: K121703

Trade/Device Name: Lipokit with disposable 50cc AFT Syringe

Regulation Number: 21 CFR 878.5040

Regulation Name: Suction lipoplasty system

Regulatory Class: Class II Product Code: MUU Dated: November 15, 2012

Received: November 20, 2012

### Dear Mr. Enyinna:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

# Peter D. Rumm -S

Mark N. Melkerson
Acting Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

**510(k) Number (if known):** K121703

# **Indications for Use Statement**

Device Name: Lipo	kit with disposable 50cc AFT S	yringe
Indications for Use The Lipokit is used filtering and trans	: in the tumescent injection, as erring of autologous fat tissue	piration, harvesting,
The Lipokit is inte	nded for use in the following sun of the soft tissue is desired:	ırgical specialties
<ul><li>Plastic and I</li><li>General Sur</li><li>Dermatologi</li></ul>	Reconstructive Surgery gery cal Surgery & Gynecological Surgery	
The Lipokit is indicated for use when harvesting of highly concentrated pure fatty tissues for aesthetic body and facial contouring is desired.		
ч .		
Prescription UseX	AND/OR	Over-The-Counter Use
(Part 21 CFR 801 Subpart	D) /////	(21 CFR 801 Subpart C)
(PLEASE DO NOT PAGE OF NEEDED	WRITE BELOW THIS LINE-CON )	ITINUE ON ANOTHER
Concurrence of CI	ORH, Office of Device Evaluatio	n (ODE)
- A	David Krause	A B
2	(Division Sign-Off)	

Division of Surgical Devices 510(k) Number: K121703